Azithromycin: effects for treating COVID-19 are uncertain (search done on 16 April 2020)

Added July 13, 2020

Citation: Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP open. 2020 Jun 23;4(2):bjgpopen20X101094

What is this? Azithromycin has been suggested as possible treatment for COVID-19 patients.

In this rapid review, the authors searched for in vivo and in vitro studies assessing the safety and effectiveness of azithromycin for treating COVID-19 patients. They restricted their searches to articles published from 2019 onwards, but did not restrict by language of publication and did the search on 16 April 2020. They included two in vitro studies and one in vivo study, which were all published as pre-prints.

What was found: At the time of this review, the available evidence on the effects of azithromycin for treating COVID-19 patients was very limited and the potential benefits and harms were uncertain.

 

Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.

Share